DexComDXCM -0.23%90 9-Day RSI is 45.18 as of Jun. 29, 2026. GuruFocus rates DXCM with a GF Score™ of 90/100 and a GF Value™ of $103.58 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 870 Medical Devices & Instruments companies, DexCom ranks worse than 55.86% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-06-29), DexCom's 9-Day RSI is 45.18.
The industry rank for DexCom's 9-Day RSI or its related term are showing as below:
DXCM's 9-Day RSI is ranked worse than 55.86% of 870
companies
in the Medical Devices & Instruments industry
Industry Median: 42.585
vs DXCM: 45.18
DexCom (NAS:DXCM) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
DexCom 9-Day RSI Related Terms
DXCM vs GEHC, STE, ZBH: 9-Day RSI Comparison
For the Medical Devices subindustry, DexCom's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexCom 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, DexCom's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where DexCom's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DexCom (DXCM) has a 9-Day RSI of 45.18 as of Jun. 29, 2026. According to the industry distribution chart, DexCom ranks #486 out of 870 companies in the Medical Devices & Instruments industry, placing it in the top 55.9%.
Is DexCom's 9-Day RSI too high?
DexCom's current 9-Day RSI is 45.18. The Medical Devices & Instruments industry median 9-Day RSI is 42.59. DexCom's value of 45.18 is 6.1% above this industry median. Based on the distribution chart, DexCom ranks #486 out of 870 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, DexCom has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DexCom's 9-Day RSI compare to GEHC and STE?
According to the Medical Devices & Instruments industry distribution chart, DexCom ranks #486 out of 870 companies for 9-Day RSI. This places DexCom in the lower half of its industry. The industry median 9-Day RSI is 42.59. DexCom's value of 45.18 is 6.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 42.59, based on 870 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DexCom's current 9-Day RSI of 45.18 is 6.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 42.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexCom's current 9-Day RSI is 45.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (DXCM) is currently considered Significantly Undervalued. The stock's GF Value™ is $103.58, compared to a current price of $69.98 — trading 32.4% below its estimated fair value. The current 9-Day RSI is 45.18 and 6.1% above the Medical Devices & Instruments industry median of 42.59. DexCom's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For DexCom (DXCM), the current 9-Day RSI is 45.18 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DexCom (DXCM) Overvalued in 2026?
Based on GuruFocus' analysis, DexCom stock appears to be undervalued.
The current stock price of $69.98 is trading 32.4% below its estimated GF Value™ of $103.58.
GuruFocus considers DexCom to be Significantly Undervalued.
Key valuation signals for DXCM:
9-Day RSI: 45.18
GF Value™: $103.58 vs. price of $69.98 (32.4% below fair value)
Industry Position: 6.1% above the Medical Devices & Instruments median (#486 of 870)
No single metric tells the full story. See the DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
90GF Score
Get the complete analysis for DXCM
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DXCM has been successfully added to your 